Germany-based biopharmaceutical company Rigontec has extended a series A round featuring Boehringer Ingelheim Venture Fund, the investment arm of pharmaceutical company Boehringer Ingelheim to almost €14.3m ($15.6m).

Venture capital firms Forbion Capital Partners and Sunstone Capital provided the €4.8m for the second tranche.

Rigontec raised €9.45m in October 2014 from backers including Boehringer Ingelheim, German government and corporate-backed VC fund High-Tech Gruenderfonds (HTGF), NRW.Bank and Wellington Partners.

Founded in January 2014, Rigontec has developed treatments that can destroy diseased cells…